A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell Lymphoma
A phase 2 trial of Rocbrutinib, Bendamustine, Rituximab in diffuse large b-cell lymphoma, run by Guangzhou Lupeng Pharmaceutical Company LTD., now recruiting.
Overview
A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell Lymphoma is a phase 2 interventional study registered as NCT07189065 by Guangzhou Lupeng Pharmaceutical Company LTD., with 150 participants planned, started 2025-11-27 and due to reach its primary completion in 2027-12-31. Interventions recorded: Rocbrutinib, Bendamustine, Rituximab, Lenalidomide. Conditions listed: Diffuse Large B-Cell Lymphoma (DLBCL). No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study of Rocbrutinib in Combination With Lacutoclax in Patients With B-Cell Malignancies
Shares Rocbrutinib, Diffuse large B-cell lymphoma.
- TrialBrentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL
Shares Lenalidomide, Rituximab, Diffuse large B-cell lymphoma.
- TrialA Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma
Shares Lenalidomide, Rituximab.
- TrialA Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma
Shares Bendamustine, Lenalidomide, Rituximab.
- TrialA Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcita
Shares Lenalidomide, Rituximab, Diffuse large B-cell lymphoma.
- TrialA Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL
Shares Bendamustine, Rituximab.
- TrialA Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Shares Bendamustine, Rituximab.
- CompanyBiogen
Shares Rituximab, Diffuse large B-cell lymphoma.